Scientific Program
Opening Ceremony
19:00 - 20:00
Opening Speech
  • Welcoming and Registration


    17:00 - 20:30
  • Opening Remarks

    Taghrid Alhowish
    20:30 - 20:45
  • Speech of SSCP Founding President

    Prof.Ahmed Aljedai
    20:45 - 20:50
  • Speech of CEO of Saudi Food and Drug Authority

    H.E prof. Hisham Aljadhey
    20:50 - 20:55
  • Live performance


    20:55 - 21:10
  • Keynote Speech: Healthcare Innovation and Leadership

    Dr. Tareef Alaama
    21:10 - 21:25
  • SSCP video


    21:25 - 21:30
  • Awards Ceremony


    21:30 - 22:00
Keynote Speech: Healthcare Innovation and Leadership
19:30 - 20:00 Dr. Tareef Alaama
  • Keynote Speech

    Dr. Tareef Alaama
    19:30 - 20:00
Satellite Symposium
10:30 – 11:00 The economic burden of obesity and the added value in obesity management Dr. Ibrahim Alhomoud
Session 1
Biotechnology, Clinical Research, and Breakthrough Innovations
Moderator: Dr. Nada Alsuhebany
  • Bridging academia and industry in biotech innovation

    Dr. Nadin Almosnid
    UAN # 0662-0000-25-010-L99-P
    08:10 - 08:30

    Objectives:

    1. Describe the roles, structures, and objectives of academic institutions and biotechnology companies.
    2. List examples of successful academic–industry partnerships in the biotechnology sector.
    3. Discuss common strategies used to initiate collaboration between pharmacy faculties and industry stakeholders.

  • Innovation and entrepreneurship in pharmacy: from biotech research to healthcare solutions

    Dr. Abdulrahman Alshaya
    UAN # 0662-0000-25-011-L99-P
    08:30 - 08:50

    Objectives:

    1. Discuss the importance of biotech innovation in the pharmacy market
    2. Describe entrepreneurial pathways pursued in the Middle East versus globally
    3. Explain the value proposition of a biotech-based startup addressing local healthcare gaps
  • Advancing clinical research in healthcare through professional educational programs

    Dr. Ahmed Aldemerdash
    UAN # 0662-0000-25-012-L99-P
    08:50 - 09:10

    Objectives:

    1. Identify the essential components of professional programs designed to build clinical research capacity.
    2. Describe the key competencies that clinical pharmacists are expected to acquire through continuing education.
    3. Discuss existing educational offerings and common approaches for their improvement in the context of Saudi clinical practice.
  • Biotechnology and value-based healthcare: aligning innovation with outcomes in Saudi Arabia

    Dr. Hajer Almudaiheem
    UAN # 0662-0000-25-013-L99-P
    09:10 - 09:30

    Objectives:

    1. Identify key metrics used in evaluating value-based healthcare outcomes
    2. Explain the relationship between biotechnological advancements and healthcare value
    3. Discuss a framework for integrating biotech innovations into value-based models in Saudi healthcare institutions
  • Driving clinical research excellence in Saudi Arabia

    Dr. Abdulrazaq Aljazairi
    UAN # 0662-0000-25-014-L99-P
    09:30 - 09:50

    Objectives:

    1. Discuss the critical factors for clinical research excellence in Saudi Arabia
    2. Illustrate how national policies and funding influence research productivity
    3. Describe a roadmap to elevate research standards aligned with Vision 2030.
  • Panel Discussion

    All
    09:50-10:00
Special Panel 1
Healthcare Accessibility and Universal Coverage
Moderator: Dr. Omar Alshaya
  • Healthcare Accessibility and Universal Coverage

    Dr. Nasser Aljehani
    Dr. Shaker Alomary
    Dr. Nawaf Albali
    11:00 - 11:50
Session 2
Pharmacy in National and International Health Transformation and Digitalization
Moderator: Dr. Hisham Badreldin
  • Artificial intelligence integration in clinical decision support: Paving the path to smarter pharmacy practice

    Prof. Ahmed Aljedai
    UAN # 0662-0000-25-015-L99-P
    13:00 - 13:20

    Objectives:

    1. Describe the role of artificial intelligence (AI) in clinical decision support systems relevant to pharmacy practice.
    2. Recognize challenges associated with AI-driven clinical decision support systems.
    3. Explain key considerations pharmacists should be aware of when using AI-driven clinical decision support systems.
  • Professional transformation of clinical pharmacy education

    Dr. Michael Maddux
    UAN # 0662-0000-25-016-L99-P
    13:20 - 13:40

    Objectives:

    1. Summarize the evolution of clinical pharmacy.
    2. Identify innovative strategies that support clinical pharmacy education and training.
    3. Describe important trends in contemporary clinical education and training.
    4. Explain future goals for the transformation of clinical pharmacy education and training.
  • Activating virtual healthcare: strategies for a digital future

    Dr. Abdulaziz Alhomod
    UAN # 0662-0000-25-018-L99-P
    13:40 - 14:00

    Objectives:

    1. Describe best practices for designing and implementing virtual care services.
    2. Explain regulatory, ethical, and data privacy considerations in virtual healthcare services.
    3. Recognize real-world examples of virtual services and their impact on the healthcare industry.
  • Panel Discussion

    ALL
    14:00 - 14:30
Special Panel 2
Pharmacy Role in Global Events Preparedness
Moderator: Dr. Ahmed Aldemerdash
  • Pharmacy Role in Global Events Preparedness

    Dr. Jameel Abualenain
    Dr. Anas Khan
    Dr. Mohammed Alshennawi
    Dr. Abdulrhman Mohana
    15:30 - 16:20
Special Panel 3
Transforming Pharmacists & Pharmacy Technicians Education
Moderator: Prof. Ahmed Alalaiwe
  • Transforming Pharmacists & Pharmacy Technicians Education

    Prof. Abdulkareem Albekairy
    Prof. Amer Alanazi
    Dr. Ahmed Aljabri
    Dr. Manal Alem
    Dr. Abdulaziz Almulhim
    10:00 - 10:50
Session 3
Localizing the Industry, Green Initiatives/Healthcare, and Supply Chains
Moderator: Dr. Mohammed Alshennawi
  • Green healthcare: sustainable strategies for medical waste reduction

    Dr. Abdulaziz Aljodai
    UAN # 0662-0000-25-019-L99-P
    14:30 - 14:50

    Objectives:

    1. Identify the key sources of medical waste in healthcare institutions.
    2. Explain the environmental and public health impact of improper medical waste management.
    3. Describe components of a sustainable medical waste management plan for a healthcare institution.
  • Panel Discussion

    15:30 - 15:40

    All
    15:30 - 15:40
Special Panel 4
The Expanding Role of Clinical Pharmacists Beyond Hospitals. Global Leadership of Pharmacists: All the Know-Hows to be a Global Leader
Moderator: Dr. Abdulaziz Alqahtani
  • The Expanding Role of Clinical Pharmacists Beyond Hospitals. Global Leadership of Pharmacists: All the Know-Hows to be a Global Leader

    Dr. Abubker Omaer
    Dr. Omaima Arab
    Dr. Rafia Jamil
    Dr. Michael Maddux
    16:00 - 16:50
Session 4
Advancements in Critical Care: Key Updates and Debates in ICU Pharmacotherapy | Moderator: Dr. Bassam Aldakheel
  • Advances in ICU pharmacotherapy: a year in review

    Dr. Abdullah Alhammad
    UAN # 0662-0000-25-022-L01-P
    08:20 - 08:40

    Objectives:

    1. Summarize key pharmacotherapy updates in critical care published over the past year.
    2. Describe the quality and applicability of recent ICU pharmacotherapy trials.
    3. Identify the relevance of new evidence to local ICU practice and protocols.
  • Research gaps in heat stroke management

    Dr. Namareq Aldardeer
    UAN # 0662-0000-25-023-L01-P
    08:40 - 09:00

    Objectives:

    1. Summarize the existing literature on heat stroke management.
    2. Describe the limitations of current research and how gaps may impact frontline care.
    3. Identify potential areas for research to address gaps in heat stroke management.
  • Debate: etomidate vs. ketamine for rapid sequence intubation

    Dr. Christopher Edwards
    Dr. Muhannad Abdulmajeed
    UAN # 0662-0000-25-024-L01-P
    09:00 - 09:40

    Objectives:

    1. Recall the key pharmacological differences and clinical indications of etomidate and ketamine for rapid sequence intubation.
    2. Summarize clinical trial evidence comparing etomidate and ketamine regarding safety and efficacy in rapid sequence intubation.
    3. Identify considerations for developing evidence-based recommendations for institutional protocols and clinical scenarios.
  • Panel Discussion

    09:40 - 09:50

    All
    09:40 - 09:50
Session 5
Pharmacy Leadership and Representation in International Domains
Moderator: Dr. Abdullah Alzeer
  • Global positioning of Saudi Arabia in the drug regulation landscape (recent recognitions of SFDA)

    Dr. Hussain Bafagih
    UAN # 0662-0000-25-025-L99-P
    10:00-10:20

    Objectives:

    1. Explain the significance of SFDA’s recognitions in the global drug regulatory landscape.
    2. Describe how SFDA’s regulatory standards align with those of other leading global agencies.
    3. Identify the impact of SFDA’s global positioning on the pharmaceutical industry in Saudi Arabia.
    4. Summarize the importance of SFDA’s recognitions in the global drug regulatory environment.
  • Future of pharmacy and the role of ACCP: Enhancing global collaboration and professional recognition

    Dr. Michael Maddux
    UAN # 0662-0000-25-026-L99-P
    10:20-10:40

    Objectives:

    1. Define global trends shaping clinical pharmacy.
    2. Describe the evolving roles of clinical pharmacists in acute, ambulatory, and community care settings.
    3. Explain how digital health is transforming pharmacy services.
    4. Identify high-impact strategies for collaboration and capacity building.
    5. Explain the value of recognition and credentialing for quality and sustainability.
    6. Outline ACCP contributions and near-term actions relevant to your practice setting.
  • Empowering community pharmacies to lead healthcare transformation

    Dr. Mohammed Alshennawi
    UAN # 0662-0000-25-027-L99-P
    10:40-11:00

    Objectives:

    1. Explain the importance of empowering community pharmacies in healthcare delivery.
    2. Describe strategies that can enhance the role of community pharmacists.
    3. Identify barriers to expanding clinical services in community pharmacies.
  • From policy to practice: the role of clinical pharmacy leaders in system-wide change

    Dr. Rafia Jamil
    UAN # 0662-0000-25-028-L99-P
    11:00-11:20

    Objectives:

    1. List the key responsibilities of clinical pharmacy leaders in healthcare systems.
    2. Explain how clinical pharmacy leaders translate policy into practice.
    3. Identify key elements involved when clinical pharmacy leaders guide system-wide change from policy development to practice implementation.
  • Navigating pharmaceutical practice and leadership in the corporate world

    Dr. Hala Joharji
    UAN # 0662-0000-25-029-L99-P
    11:20-11:40

    Objectives:

    1. Identify key leadership competencies required in the pharmaceutical corporate environment.
    2. Describe effective communication strategies for pharmacists working in corporate settings.
    3. Explain the impact of corporate culture on pharmaceutical leadership and decision-making.
    4. List factors that influence leadership effectiveness in pharmaceutical companies.
  • Panel Discussion

    All
    11:40-11:50
Session 1
Cardiology in the Fast Lane: Latest Pharmacotherapy Advances | Moderator: Dr. Yahya Tawfik
  • Beyond statins: innovative dyslipidemia management strategies – stepwise vs. comprehensive approach

    Dr. Omar Alkhezi
    UAN # 0662-0000-25-030-L99-P
    08:30 - 08:50

    Objectives:

    1. Summarize the key features and mechanisms of novel nonstatin therapies used in dyslipidemia management.
    2. Describe the stepwise and comprehensive approaches to dyslipidemia management, including their advantages and disadvantages.
    3. Identify discrepancies between current practice and local and international guidelines for dyslipidemia management.
    4. List strategies commonly used to improve compliance in noncompliant patients.
  • Advancing acute coronary syndrome care: updates and emerging strategies

    Dr. Sanaa Alsulami
    UAN # 0662-0000-25-031-L01-P
    08:50 - 09:10

    Objectives:

    1. Summarize the key updates in the 2025 Acute Coronary Syndrome (ACS) guidelines.
    2. Describe the evidence supporting shorter Dual Antiplatelet Therapy (DAPT) duration.
    3. Explain the new evidence regarding prolonged beta-blocker therapy in patients with preserved LVEF post-ACS.
  • Revolutionizing hypertrophic cardiomyopathy: breakthrough therapies and emerging treatments

    Dr. Arif Albulushi
    UAN # 0662-0000-25-032-L01-P
    09:10 - 09:30

    Objectives:

    1. Summarize the latest breakthrough therapies for hypertrophic cardiomyopathy (HCM).
    2. Describe the evidence supporting emerging treatments for HCM.
    3. Identify gaps in evidence for applying new HCM therapies to the patient population.
    4. Explain the implications of new HCM therapies on patient outcomes.
  • The third-generation anticoagulants: Exploring the potential of factors XI, XII, and XIII inhibitors

    Dr. Ahlam Althobaiti
    UAN # 0662-0000-25-033-L01-P
    09:30 - 09:50

    Objectives:

    1. Summarize the mechanisms of action and clinical applications of third-generation anticoagulants targeting factors XI, XII, and XIII.
    2. Describe the recent evidence supporting the efficacy and safety of these third-generation anticoagulants.
    3. Identify gaps in evidence for applying these anticoagulants to specific patient populations.
  • Panel Discussion

    All
    09:50 - 10:00
Track | Entrepreneurship
Moderator: Abdulaziz Areekan
  • The Journey from Healthcare Professional to Entrepreneur

    Mr. Ameer Albahouth
    10:00-10:20
  • The Entrepreneurial Mindset: Turning Unmet Needs into Virtual Reality Wellness Solutions

    Dr. Ibrahim Almaghlouth
    10:20-10:40
  • Seha Virtual Hospital Journey: Redefining Healthcare Through Innovation and Virtual Excellence

    Dr. Ibrahim Al Baalharith
    10:40-11:00
  • Innovative Pathways to Attract Investment: Turning Bold Ideas into Business Growth

    Eng. Fahd Ghzwani
    11:00-11:20
  • Panel Discussion

    All
    11:20 -11:50
Track - Personal development
Leading with Your Personal Brand: Discovering Identity & Building Impact - Ms. Suzan Riad
Track | Investment
Moderator: Dr. Rabab khodary
  • Special Panel: The Art of Valuation and Value Creation in Startups

    Mr. Faisal Abdulsalam Mr. Abdulaziz Alobaid
    15:00-15:45
  • Biotech Investment in Saudi Arabia

    Dr. Budoor Almansour
    15:45-16:10
  • Future of Healthcare Investment in Saudi Arabia

    Dr. Ibrahim Alnajashi
    16:10-16:30
  • Panel Discussion

    All
    16:10-16:30
Session 3
Pediatric Pharmacotherapy Advances: Key Updates and Challenges
Moderator: Prof. Majed Aljeraisy
  • This dose, that dose, which dose, what dose: how to select a dose when references don’t match up

    Dr. Jamie Miller
    UAN # 0662-0000-25-038-L01-P
    09:00 - 09:20

    Objectives:

    1. Describe potential reasons why dosing recommendations may differ for premature neonates between published references.
    2. Summarize literature supporting recent updates to medication dosing in tertiary sources.
    3. Identify the appropriate dose to use for a premature neonate given a specific medication scenario.
  • Cystatin-C in pediatrics: from lab to bedside how it works

    Dr. Majed Nahari
    UAN # 0662-0000-25-039-L01-P
    09:20 - 09:40

    Objectives:

    1. Describe the mechanisms underlying the production and clearance of Cystatin-C and its correlation with glomerular filtration rate (GFR) in pediatric populations.
    2. Identify differences between Cystatin-C and traditional biomarkers, such as serum creatinine, in evaluating kidney function in children.
    3. Explain current challenges and potential advancements in implementing Cystatin-C testing for early detection and monitoring of pediatric kidney function.
  • Optimizing pharmacotherapy in pediatric metabolic disorders and rare diseases in Saudi Arabia

    Dr. Abdullah Almalki
    UAN # 0662-0000-25-040-L01-P
    09:40 - 10:00

    Objectives:

    1. Describe the current landscape and challenges of diagnosing and managing rare pediatric metabolic conditions in Saudi Arabia.
    2. Explain evidence-based strategies and clinical guidelines for optimizing pharmacotherapy in pediatric patients with metabolic and rare disorders.
    3. Identify national initiatives, registries, and case studies from Saudi Arabia that support precision and personalized medicine in pediatric rare diseases.
  • Checking the List: agents to avoid and use with caution in children

    Dr. Jamie Miller
    UAN # 0662-0000-25-041-L01-P
    10:00 - 10:20

    Objectives:

    1. Identify the purpose of the KIDs List.
    2. List medications that are contraindicated or should be used with caution in pediatric patients.
    3. Explain the rationale for avoiding or cautiously using certain medications in children.
  • Identifying and reporting child abuse cases in Saudi Arabia

    Dr. Fadiah Alkhattabi
    UAN # 0662-0000-25-042-L01-P
    10:20 - 10:40

    Objectives:

    1. Define the types and signs of child abuse, emphasizing clinical indicators observable in healthcare settings.
    2. Describe the legal and ethical responsibilities of clinicians in identifying and reporting suspected child abuse in Saudi Arabia.
    3. Identify common barriers to reporting child abuse and strategies to overcome them in clinical practice.
    4. Recognize real-world case examples that illustrate effective clinician intervention and multidisciplinary collaboration.
  • Panel Discussion

    All
    10:40 - 10:50
Track | Leadership
  • Special Panel: Beyond the Titles: Honest Journeys of Women Redefining Leadership

    Tuba Terekli and Dr. Amal Almoudi
    15:00 - 15:30
  • Special Panel: Navigating Uncertainty: Leadership in a Rapidly Evolving Healthcare Landscape

    Dr. Faisal Alnemary and Ms. Dina Alismail
    15:45 - 16:45
  • Special Panel: Youth Leadership, Diplomacy, and Intercultural Dialogue

    TBA
    16:45 - 17:45
Track | Investment
Moderator: Mr. Ziad Alsarour
  • From Hype to Reality: How Blockchain is Reshaping the World

    Mohammed Aljasser
    13:30 -13-55
  • How to Build Your Investment Plan to Achieve Your Future Goals?

    Faisal Alqarni
    13:55 -14:20
  • Panel Discussion

    All
    14:20 -14:50
Track | Personal Development
  • Project Management Excellence: Strategic Planning and Execution as the Foundation for Driving Innovation.

    Eng. Mohammed Shalan
    9:00 - 10:00
Session1
Advancing Ambulatory Care Pharmacy: Innovations, Challenges, and Future Directions
Moderator: Dr. Abdulaziz Alqahtani
  • The value proposition of pharmacist-led clinics: enhancing health and economic outcomes in healthcare systems

    Prof. Abdulaziz Alhossan
    UAN # 0662-0000-25-051-L99-P
    10:00 - 10:20

    Objectives:

    1. Explain the role of pharmacist-led clinics in improving patient health outcomes.
    2. Describe how pharmacist-led clinics contribute to cost savings in healthcare systems.
    3. Identify examples of successful pharmacist-led clinic models from global healthcare systems.
  • Saudi Arabia’s pharmacist-led clinics: unlocking opportunities

    Dr. Bashayr Alsuwayni
    UAN # 0662-0000-25-052-L99-P
    10:20 - 10:40

    Objectives:

    1. Identify the main challenges faced by pharmacist-led clinics in Saudi Arabia.
    2. Describe opportunities for pharmacists to expand their roles in primary care, chronic disease management, and patient counseling.
    3. Explain strategies to overcome barriers and implement sustainable pharmacist-led clinics.
  • Enhancing diabetes care: a case study on pharmacist involvement in continuous glucose monitoring

    Dr. Marwah Alnewais
    UAN # 0662-0000-25-053-L01-P
    10:40 - 11:00

    Objectives:

    1. Describe the pharmacist’s role in initiating and monitoring continuous glucose monitoring (CGM) for diabetes patients.
    2. Explain the benefits of pharmacist involvement in diabetes care, including improved patient outcomes.
    3. Identify insights from a real-world case study on pharmacist-led CGM services.
  • Enhancing ambulatory care with tele-pharmacy: a new era in patient-centered services

    Dr. Raghad Alsaif
    UAN # 0662-0000-25-054-L01-P
    11:00 - 11:20

    Objectives:

    1. Describe innovations in telepharmacy that enhance ambulatory care services.
    2. Explain how telepharmacy improves patient accessibility to pharmacy services.
    3. Identify the role of telepharmacy in delivering personalized, patient-centered care.
  • Panel Discussion: advancing ambulatory care pharmacy: challenges, successes, and future directions

    Dr. Fahad Aldosari
    Dr. Sarah Abutaily
    Dr. Mohammed Alzayed
    11:20 - 11:50
Session2
Antimicrobial Therapies: Emerging Treatments and Bacterial Resistance
Moderator: Dr. Bashayer Alshehail
  • Emerging treatments for cytomegalovirus (CMV) infection

    Dr. Ahmed Taqi
    UAN # 0662-0000-25-034-L01-P
    13:30 - 13:50

    Objectives:

     1. Describe the pharmacologic targets, mechanisms of action, resistance pathways, and key pharmacokinetic/pharmacodynamic properties of recently introduced anti-CMV agents.
    2. Identify considerations for calculating and individualizing dosing regimens for emerging anti-CMV medications in clinical scenarios.
    3. Explain components of a comprehensive, patient-specific pharmacotherapy plan integrating emerging CMV treatments with clinical monitoring strategies UAN # 0662-0000-25-034-L01-P
  • Exploring the future of self-administered OPAT

    Dr. Yazed Alsowaida
    UAN # 0662-0000-25-035-L01-P
    13:50 - 14:10

    Objectives:

    1. Describe the pharmacologic, pharmacokinetic/pharmacodynamic, and device-related factors that enable patients to self-administer IV antimicrobials at home.
    2. Identify criteria for determining patient eligibility for self-administered OPAT and selecting appropriate antimicrobial therapy.
    3. Explain key components of a pharmacist-led plan for a self-administered OPAT regimen, including quality metrics for program evaluation.
  • New antimicrobials 2025: what’s approved, what’s coming, and how to use them wisely

    Dr. Ghadeer Almousa
    UAN # 0662-0000-25-036-L01-P
    14:10 - 14:30

    Objectives:

    1. Identify novel antimicrobials and summarize their core pharmacokinetic/pharmacodynamic properties and spectrum of activity.
    2. Describe clinical applications of novel agents, considering pathogen susceptibility, infection site, and patient factors.
    3. Explain emerging clinical and post-marketing data supporting safe and effective use.
    4. Recognize the role of interprofessional collaboration and evidence-based practice in optimizing antimicrobial use and combating resistance.
  • Bacterial resistance: where do we stand with novel antimicrobials for bacterial resistance

    Dr. Reem Almahasnah
    UAN # 0662-0000-25-037-L01-P
    14:30 - 14:50

    Objectives:

    1. Describe the key resistance mechanisms driving current multidrug-resistant (MDR) pathogens and the novel drug classes developed to overcome them.
    2. Summarize recently approved and late-pipeline antibacterials by spectrum, PK/PD targets, and pivotal efficacy data.
    3. Identify components of a stewardship-oriented treatment plan integrating a novel antimicrobial, including dosing, monitoring, and resistance-mitigation strategies.
  • Panel Discussion

    All
    14:50 - 15:00
Session 3
The Latest Breakthroughs: Pharmacotherapy Advances in Hematology/Oncology
Moderator: Dr. Maha Aldoughaim
  • Exploring novel approaches to cancer vaccine development

    Dr. Hind Aboheimed
    UAN # 0662-0000-25-043-L01-P
    16:00 -16:20

    Objectives:

    1. Describe emerging immunological mechanisms underlying new cancer vaccines.
    2. Identify differences between traditional cancer therapies and recent vaccine-based treatments.
    3. Summarize clinical trial outcomes regarding the efficacy and safety of cancer vaccines.

    UAN # 0662-0000-25-043-L01-P
  • Precision in pink: advancing targeted therapies in breast cancer

    Dr. Ahmed Alanazi
    UAN # 0662-0000-25-044-L01-P
    16:20 -16:40

    Objectives:

    1. Summarize recent advancements in targeted therapies for breast cancer.
    2. Describe personalized treatment algorithms based on patient-specific biomarkers.
    3. Explain the role of pharmacists in managing resistance and toxicity in targeted treatments.

    UAN # 0662-0000-25-044-L01-P
  • Code blood: navigating hematological emergencies

    Dr. Abdullah Alrajhi
    UAN # 0662-0000-25-045-L01-P
    16:40 -17:00

    Objectives:

    1. Identify the most common hematologic crises.
    2. Describe urgent laboratory findings that indicate hematological emergencies.
    3. Explain key considerations for drug selection and dosing strategies in hematological emergency scenarios.

    UAN # 0662-0000-25-045-L01-P
  • Panel Discussion

    All
    17:00 -17:10
Session 4
Internal Medicine & Transplant Updates: Emerging Therapies and Strategies
Moderator: Dr. Bedor Alomari
  • Navigating safety profiles: GLP-1 therapy in diabetes and obesity

    Dr. Anfal Al-Ali
    UAN # 0662-0000-25-046-L01-P
    08:30 - 08:50

    Objectives:

    1. Define the mechanism of action of GLP-1 receptor agonists in diabetes and obesity.
    2. Describe the safety profiles of different GLP-1 therapies.
    3. Identify considerations for determining the appropriateness of GLP-1 therapy for obese diabetic patients.

    UAN # 0662-0000-25-046-L01-P
  • Beyond bisphosphonates: what is the next generation of therapies and prophylaxis for osteoporosis

    Dr. Maha Almolaiki
    UAN # 0662-0000-25-047-L01-P
    08:50 - 09:10

    Objectives:

    1. Describe the limitations of bisphosphonate therapy.
    2. Identify appropriate non-bisphosphonate treatment options for osteoporosis patients.
    3. Explain key components of a treatment algorithm incorporating emerging therapies for osteoporosis management.

    UAN # 0662-0000-25-047-L01-P
  • Optimizing immunosuppression: strategies for successful outcomes

    Dr. Sahar Almowaina
    UAN # 0662-0000-25-048-L01-P
    09:10 - 09:30

    Objectives:

    1. List common classes of immunosuppressive drugs used in transplant patients.
    2. Describe strategies to balance immunosuppression and infection risk.
    3. Identify common complications of immunosuppression and approaches for their prevention or management.

    UAN # 0662-0000-25-048-L01-P
  • Novel antibody-mediated rejection therapies: a pharmacotherapy perspective

    Dr. Noor Alashi
    UAN # 0662-0000-25-049-L01-P
    09:30 - 09:50

    Objectives:

    1. Explain the pathophysiology of antibody-mediated rejection.
    2. Identify pharmacologic options based on the type and timing of rejection.
    3. Describe the effectiveness of novel therapies in resistant cases of rejection.

    UAN # 0662-0000-25-049-L01-P
  • Optimizing treatment strategies for diabetic kidney disease: a pathway to managing chronic kidney disease

    Dr. Mohamed Albekery
    UAN # 0662-0000-25-050-L01-P
    09:50 - 10:10

    Objectives:

    1. Identify key therapeutic targets in diabetic kidney disease.
    2. Describe considerations for developing an individualized treatment plan for a patient with diabetic CKD.
    3. Explain components of a multi-disciplinary care pathway to optimize long-term kidney outcomes.

    UAN # 0662-0000-25-050-L01-P
  • Panel Discussion

    All
    10:10 - 10:20
Session 5
Advancing Medication Use and Safety Across the Continuum of Care
Moderator: Dr. Murooj Shukry
  • Artificial intelligence in critical care: value and limitations

    Dr. Lama Nazer
    UAN # 0662-0000-25-055-L01-P
    10:30 - 10:50

    Objectives:

    1. Describe the role of AI in critical care medicine.
    2. Identify types of bias associated with AI-based algorithms.
    3. Explain strategies to mitigate bias in AI-based solutions.
  • Digital health and home healthcare: bridging the gap in patient care in Saudi Arabia

    Dr. Abdullah Alotaibi
    UAN # 0662-0000-25-056-L99-P
    10:50 - 11:10

    Objectives:

    1. Describe digital health, including telehealth, mobile health applications, and electronic health records.
    2. Explain the advantages of home health care, such as patient comfort, reduced hospital visits, and personalized care.
    3. Identify strategies for integrating digital health solutions with home health care services to improve patient outcomes.
    4. Recognize successful examples or case studies where digital health has positively impacted home care.
    5. Describe potential future trends and technologies in digital health that could enhance home health care in Saudi Arabia.
  • The role of SFDA’s MUE initiative in improving patient outcomes

    Dr. Waad Alghamdi
    UAN # 0662-0000-25-057-L99-P
    11:10 - 11:30

    Objectives:

    1. Explain the role of the SFDA in regulating medication use and ensuring patient safety.
    2. Describe the process and importance of Medication Use Evaluation (MUE) initiatives implemented by the SFDA.
    3. Identify how MUE initiatives can improve clinical outcomes, reduce medication errors, and enhance patient adherence.
    4. Recognize the role of collaboration between healthcare providers and the SFDA in promoting effective medication management.
  • Precision deprescribing: enhancing safety and quality in high-risk medication use

    Dr. Amani Al Shaban
    UAN # 0662-0000-25-058-L99-P
    11:30 - 11:50

    Objectives:

    1. Explain the concept of deprescribing and its importance in managing high-risk medications.
    2. Describe the risks associated with polypharmacy and the adverse effects of unnecessary medications.
    3. Identify how personalized approaches can optimize medication regimens based on individual patient needs.
    4. Describe strategies and guidelines for implementing deprescribing practices in clinical settings.
    5. Explain the potential benefits of deprescribing for enhancing patient safety, quality of life, and overall health outcomes.
    6. Recognize real-world examples or case studies illustrating successful deprescribing interventions.
  • Panel Discussion

    All
    11:50 - 12:00